pyrroles has been researched along with Acquired Immune Deficiency Syndrome in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alnouti, Y; Bade, AN; Dash, PK; Edagwa, B; Gautam, N; Gelbard, HA; Gendelman, HE; Gnanadhas, DP; Gorantla, S; Lin, Z; McMillan, J; Mosley, RL; Palandri, DL; Sillman, B | 1 |
| Schmidt, C | 1 |
| Grubb, JR; Onen, NF; Overton, ET; Presti, R | 1 |
| Chapman, KT; Duffy, JL; Emini, EA; Jin, L; Kevin, NJ; Kirk, BA; Kuo, LC; Lin, JH; Olsen, DB; Rutkowski, CA; Schleif, WA; Stahlhut, M; Tata, JR | 1 |
| Bernd, C; Miles, S; Noy, A; Politsmakher, A; von Roenn, J | 1 |
| Kisanuki, S; Kiso, Y | 1 |
| Debatin, KM; Ehret, A; Frank, R; Heeney, JL; Herr, I; Krammer, PH; Westendorp, MO | 1 |
| Bentsman, G; McKinley, G; Potash, MJ; Volsky, DJ | 1 |
| Palca, J | 1 |
1 trial(s) available for pyrroles and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
New AIDS drug poised to move into development.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Benzodiazepines; Drug Evaluation; Drug Industry; Gene Products, tat; HIV; Humans; Pyrroles; tat Gene Products, Human Immunodeficiency Virus; United States | 1991 |
11 other study(ies) available for pyrroles and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-Retroviral Agents; Atazanavir Sulfate; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Female; Heterocyclic Compounds, 3-Ring; HIV-1; Humans; Macrophages; Male; Mice; Nanoparticles; Oxazines; Piperazines; Pyridines; Pyridones; Pyrroles | 2017 |
The cancer-HIV/AIDS treatment conundrum.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Cytochrome P-450 CYP3A; Drug Administration Schedule; Drug Antagonism; HIV Infections; HIV Protease Inhibitors; Humans; Indoles; Neoplasms; Pyrroles; Risk Factors; Ritonavir; Sunitinib | 2010 |
Reply to Ganesan et al.
Topics: Acquired Immunodeficiency Syndrome; Antigens, CD; Heptanoic Acids; HIV Infections; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocyte Activation; Male; Pyrroles; Receptors, CCR5; Receptors, CXCR4; RNA, Viral; T-Lymphocytes | 2012 |
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavir.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Biotransformation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Design; Drug Resistance, Viral; Drug Therapy, Combination; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Microsomes, Liver; Pyrroles; Structure-Activity Relationship | 2003 |
Fatal hepatorenal failure and thrombocytopenia with SU5416, a vascular endothelial growth factor Flk-1 receptor inhibitor, in AIDS-Kaposi's sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Angiogenesis Inhibitors; Fatal Outcome; Humans; Indoles; Liver Failure; Male; Middle Aged; Pyrroles; Renal Insufficiency; Sarcoma, Kaposi; Skin Neoplasms | 2007 |
[Anti-HIV compounds].
Topics: Acquired Immunodeficiency Syndrome; Benzodiazepinones; Gene Products, tat; HIV; HIV Protease Inhibitors; Humans; Nitroso Compounds; Pyrroles; tat Gene Products, Human Immunodeficiency Virus | 1993 |
Resistance of chimpanzee T cells to human immunodeficiency virus type 1 Tat-enhanced oxidative stress and apoptosis.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antigens, Surface; Antiviral Agents; Apoptosis; Benzodiazepines; Cell Death; Cell Line; Disease Susceptibility; Fas Ligand Protein; Gene Products, tat; Humans; Immunoglobulin M; Lymphocyte Activation; Membrane Glycoproteins; Oxidative Stress; Pan troglodytes; Pyrroles; RNA, Messenger; Species Specificity; Superoxide Dismutase; T-Lymphocytes; tat Gene Products, Human Immunodeficiency Virus; Transcription, Genetic; Tumor Cells, Cultured | 1996 |
KS trial begins.
Topics: Acquired Immunodeficiency Syndrome; Angiogenesis Inhibitors; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Male; Multicenter Studies as Topic; Patient Selection; Pyrroles; Sarcoma, Kaposi; United States | 2000 |
A Tat antagonist inhibits HIV-1 induction in naturally infected and experimentally infected T cells.
Topics: Acquired Immunodeficiency Syndrome; Animals; Antiviral Agents; Benzodiazepinones; Cell Line; Cloning, Molecular; DNA, Viral; Gene Products, tat; HIV Core Protein p24; HIV-1; Pyrroles; Rats; T-Lymphocytes; tat Gene Products, Human Immunodeficiency Virus; Tetradecanoylphorbol Acetate | 1992 |
Turnabout on AIDS drug.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Benzodiazepines; Gene Products, tat; Genes, tat; HIV; Humans; Pyrroles; tat Gene Products, Human Immunodeficiency Virus | 1992 |
Promising AIDS drug looking for a sponsor.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Benzodiazepines; Drug Industry; Humans; National Institutes of Health (U.S.); Pyrroles; Research Support as Topic; United States | 1991 |